Restenosis after stent deployment remains a major clinical problem. Antioxidants have been proposed as a promising strategy against restenosis. We tested the antioxidant probucol for its efficacy against neointimal hyperplasia in porcine coronary arteries after stent implantation. Probucol was then tested in vivo in 8 coronary arteries of 4 pigs (1000 mg/day orally beginning 7 days before stenting) and was compared to placebo (10 coronary arteries, 5 pigs) 28 days after stenting. Quantitative intravascular ultrasound (IVUS) revealed 38.8 ± 4.0 versus 40.1 ± 3.0% area stenosis in the probucol versus control group. Histopathologic assessment showed that probucol had no beneficial effect on inhibiting the neointimal proliferative response in stent lesions compared to placebo (2.35 ± 0.26 versus 2.88 ± 0.25 mm 2 ), despite similar injury scores (1.20 ± 0.12 versus 1.28 ± 0.14). An edge segment (axially 2-mm proximal to the stent margins) was assessed by IVUS. Remodeling index, which is a good marker of constrictive remodeling, was defined by the ratio of the vessel area in the lesion site (stent edge) to the vessel area in the proximal reference site (6-mm proximal to the stent margins). The remodeling index was significantly larger in the probucol group that in the placebo group (1.18 ± 0.10 versus 0.90 ± 0.06, P = 0.0012). In conclusion, probucol reduced constrictive remodeling at the edge of the implant but did not inhibit the tissue response within the stent. (Jpn Heart J 2004; 45: 305-313) 
CORONARY restenosis has been called the Achilles' heel of balloon angioplasty not only by virtue of its frequency, but also because of our inability to prevent it.
1) Attempts at solving these problems have involved the development of new devices and drugs. Recent clinical trials have established stents as the first mechanical device to reduce restenosis after balloon angioplasty. 2, 3) As a drug treatment, we reported that probucol has a beneficial effect on restenosis after balloon angioplasty in experimental and clinical studies. 4, 5) However, these results may not extend to stent restenosis because the biological features of rest-enosis in a stented vessel may differ from those after angioplasty. 6) Theoretically, antioxidants favorably influence the progression of restenosis after stent implantation 7, 8) because probucol inhibited smooth muscle cell proliferation, which plays a major role in in-stent restenosis. Otherwise, the development of new stenotic lesions at the stent edge was an additional limitation after stent therapy. Inadequate stent coverage of the injured segment by the balloon has reproduced the edge effect with a stent. Probucol is effective in reducing restenosis after balloon angioplasty. Therefore, combination stent and antioxidant therapy is expected to prevent in-stent and stent edge restenosis after stent deployment.
The porcine model of restenosis has been helpful in elucidating the cellular process of restenosis since this process appears to closely approximate that in human cases. 9) Thus, a porcine restenosis model is a feasible means with which to research the efficacy of anti-restenotic agents. The specific hypothesis of this study is that systemic probucol might limit neointimal hyperplasia in a pig coronary stent model.
METHODS
This study was performed with the approval of the Animal Care and Use Committee of Juntendo University. Animals: The pigs were allocated at random into a control group (n = 5) and a probucol group (n = 4). Probucol was administered once daily at a dose of 1,000 mg. The placebo group received capsules containing soybean oil. Therapy was started 7 days before stenting and continued for 28 days until euthanasia. Angioplasty was performed in the left anterior descending, circumflex, or right coronary artery of juvenile swine (30 to 35 kg). The stenting methods have previously been described elsewhere. 10) This model has been used in numerous prior studies and appears to reflect clinical results quite well. A 15-mm coil stent was placed and mounted on a 20-mm noncompliant balloon. Before stent deployment, the animals underwent angiograms and intravascular ultrasound studies. Oversizing was achieved at a balloon to artery diameter ratio of 1.1 to 1.2. Inflation of the balloon forced the stent into the wall of the coronary artery, resulting in arterial injury. Fluoroscopy with contrast injection immediately after balloon inflation confirmed adequate stent expansion and vessel patency. The operator was unaware of the treatment group assignment. The pigs were fed a standard laboratory chow without cholesterol supplementation. Blood was collected from all animals before the first administration, on the day of stent implantation, 7 days after stent implantation, and the day after the final administration. Plasma concentrations of probucol and α-tocopherol were measured with an HPLC-ECD system. The plasma total cholesterol and lipoprotein profiles were analyzed with an autoanalyzer and by gel permeation chromatography, respectively. Morphometric analysis of tissue: Twenty-eight days after the procedure, repeat angiography and intravascular ultrasound imaging (IVUS) were performed. The imaging was performed using an automatic pullback device, and the studies were recorded on 1/2-inch high-resolution s-VHS tapes for off-line volumetric assessment. IVUS analysis included the external elastic membrane (EEM), stent area, proliferative intimal area, and luminal cross sectional areas within the stent. An edge segment (axially 2-mm proximal to the stent margins) was assessed by IVUS. Remodeling index was defined by the ratio of the vessel area in the lesion site (edge segment) to the vessel area in the proximal reference site (axially 6-mm proximal to the stent margins). After euthanasia, the coronary artery was harvested and perfused with 10% buffered formalin. The balloon-injured coronary artery segments were processed for paraffin embedding, and the stented coronary artery segments were processed for plastic embedding, staining (hematoxylineosin, and elastic van Gieson stains), and histomorphometric analysis of 6 sections from the proximal aspect through the distal margin of the balloon-injured segment using published methods.
11) These sections were examined under a microscope and their areas were measured using a KS-400 image analyzing system (Carl Zeiss Vision GmbH, Hallbermoss, Germany). Computer-assisted planimetry was used to measure luminal area, internal elastic lamina area (area within the perimeter of the internal elastic lamina), vessel area (area within the perimeter of the external elastic lamina), and maximal neointimal thickness (determined by drawing a radial line from the lumen border to the internal elastic lamina at the point of maximal neointima). In stented arteries, the injury score and the neointimal thickness were determined at each wire site, and the mean injury scores and neointimal responses were calculated for each stented coronary segment as described by Schwartz, et al. 9) Histological analysis was performed by observers blinded to the experimental groups. Statistical analysis: All data are presented as the mean ± SD. Comparisons between the treatment and control groups were conducted using Student's unpaired 2-tailed t test. Statistical analysis was performed on the injured segments and neointima at each wire site. Regression modeling was used to account for relationship between the injury and injury-dependent neointimal response. Three models were used to establish whether there were any differences in the intercepts, slopes, or both intercepts and slopes across the two groups studied. This was performed as previously described. 12) Differences between the treatment group and control group were analyzed by the Tukey-Kramer multiple comparison t test. Differences with a P < 0.05 were considered statistically significant.
RESULTS
Each group of animals was matched for age and weight at the start of the experiment. The weight gain and final weight did not differ significantly between the groups. All animals survived without any adverse complications. The plasma concentration of probucol was 8.3 ± 0.9 µg/mL at 7 days after the start of administration and 9.6 ± 1.3 µg/mL the day after the final administration. These plasma concentrations were similar to the levels in humans. The control group had no detectable levels at any time point. α-Tocopherol was significantly decreased by 40% in the probucol group compared to control (0.28 ± 1.3 µg/mL vs 0.47 ± 1.3 µg/mL). The lipid profiles were similar in both groups (Table I) .
IVUS measurements:
The results of serial IVUS measurements are shown in Table II . No significant differences in lumen area or neointimal area in the stenting sites were observed between the two groups at four-weeks of follow-up. In the proximal edge site, lumen area and vessel area were 8.34 mm 2 , respectively, in the placebo group (Figure 1 ). These differences were not statistically significant between the groups. However, the remodeling index at follow-up in the probucol group was significantly larger than that in the control group (1.18 ± 0.10 versus 0.90 ± 0.06, P = 0.0012). Positive remodeling was observed in the probucol group whereas constrictive (or negative) remodeling occurred in the placebo group. 
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T-Chol = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides. Pathological measurements: The vessel area in the treated and control groups did not differ. No significant differences in %stenosis were observed between the two groups at four-weeks of follow-up. As shown in Figure 2 , proliferative neointima was observed at 28 days after stenting in both groups. Quantitative analysis showed that there was no difference in neointimal hyperplasia between the two groups (2.35 ± 0.26 versus 2.88 ± 0.25 mm 2 , P = 0.180) as shown in Table III and the mean injury score was similar in both groups (1.20 ± 0.11 versus 1.28 ± 0.14, P = 0.644). The relationship between depth of the arterial injury and neointimal thickness was determined for both the probucol and control groups. Figure 3 illustrates the correlation between neointimal thickness and the injury score. These results indicate that the intercepts and the slopes did not differ significantly between the groups. The measured neointimal thicknesses were similar in both groups for the same degree of injury. 
DISCUSSION
The results of this study have shown that probucol was not significantly more effective than placebo in reducing neointimal hyperplasia as measured by histological analysis and IVUS in pig coronary in-stent lesions. However, probucol inhibits the development of constrictive remodeling on the adjacent reference segment ("edge effect").
In the present study, probucol did not prevent restenosis as was observed at 6 months in the Canadian Antioxidant Restenosis Trial (CART-1). 13) In the CART-1 trial, the lumen area at follow-up in the probucol group was significantly larger than the placebo group (3.98 mm 2 versus 2.84 mm 2 ). Consequently, probucol reduces restenosis after stenting compared to placebo. The lower restenosis in the probucol group can be explained by the fact that the stent and lumen areas in the probucol group were larger than placebo in the baseline IVUS findings group (7. ) was observed by IVUS analysis. This finding agrees with our results in which probucol did not prohibit neointimal hyperplasia after stent deployment.
An interesting finding of this study is that probucol reduced constrictive remodeling at the edge of the implant but did not inhibit the tissue response within the stent. The development of new stenotic lesions at the stent edge has been a limitation of stenting. This effect has been observed in balloon sites and may relate to vessel injury (injury but not stent cover) at the edges of the treatment zone. In the probucol group, the remodeling index was 1.18 ± 0.10 whereas it was 0.90 ± 0.06 in the control group. The lower remodeling index at the edge of the stent was not the result of intimal hyperplasia, but rather to constrictive remodeling, similar to postangioplasty restenosis. 14) The increase in the remodeling index observed after coronary stenting in this porcine model is consistent with a previous report that the antirestenosis effect due to probucol after balloon angioplasty is not due to the inhibition of intimal hyperplasia but rather to favorable remodeling. 15) Vascular injury by balloon angioplasty induces oxidative stress that impairs endothelial cell function. The severity of constrictive remodeling was reported to correlate with endothelial function. 16) Probucol enhanced reendothelization and endothelial function in balloon-injured rabbit aorta. 17) These effects of probucol may be expected to reduce constrictive remodeling. Although these mechanisms would be expected to contribute to prevention of the negative remodeling, these effects do not necessarily and adequately account for the stent restenosis. However, probucol inhibits smooth muscle cell (SMC) proliferation, which plays an important role in in-stent restenosis. Experimental studies have shown that probu-col is effective in preventing intimal hyperplasia through the inhibition of SMC proliferation in a balloon injury model. 18) In contrast, probucol failed to inhibit neointima in this stent model. There are many differences in the vascular biological response to injury between balloon injury and stent models. The more robust and chronic inflammatory response to stenting requires larger and more frequent dosing than that required after simple balloon endothelial denudation. 19) This is one potential mechanism by which neointimal proliferation may not have been attenuated by probucol in this study. Experiments were performed in normocholesterolemic pigs, and serum lipid profiles were kept constant throughout the study in placebo and treated animals. Thus, the beneficial effect of probucol therapy on remodeling in our study is probably not the result of its hypocholesterolemic action. Limitations of the study: First, normal coronary arteries were used for stent implantation, in contrast to the general application in humans to treat atherosclerotic lesions, which may respond differently to the vascular injury. Second, the analysis was conducted for only 28 days after stent implantation, and this shortterm follow-up might not characterize the full process of healing after stent injury.
In conclusion, probucol administration was not associated with an improvement in the tissue response within the stent compared to placebo, although probucol did reduce constrictive remodeling at the edge of the stent.
